On May 17, 2018 Buy Rating Received VolitionRx (OTC:VNRX) at Maxim Group with $6 Target.

May 17, 2018 - By Michael Day

VolitionRx Limited (NYSEAMERICAN:VNRX) Corporate Logo

During 2017 Q4 the big money sentiment decreased to 1.2. That’s change of 5.80, from 2017Q3’s 7. 3 investors sold all, 2 reduced holdings as VolitionRx Limited ratio dived. 4 grew stakes while 2 funds acquired stakes. Funds hold 4.52 million shares thus 51.36% less from 2017Q3’s 9.30 million shares.

3,823 are held by Brown Brothers Harriman And. Vanguard Gp holds 0% in VolitionRx Limited (NYSEAMERICAN:VNRX) or 204,994 shs. Garrison Bradford And Assocs reported 0.04% in VolitionRx Limited (NYSEAMERICAN:VNRX). Blackrock Inc holds 11,219 shs or 0% of its capital. Northern Trust owns 22,714 shs. Royal Commercial Bank Of Canada owns 14,007 shs or 0% of their US capital. Bessemer Gp stated it has 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). Knoll Cap Mngmt L P holds 0.91% or 351,538 shs in its capital. Bankshares Of Mellon holds 0% in VolitionRx Limited (NYSEAMERICAN:VNRX) or 10,335 shs. Geode Cap Mngmt Limited Liability Co accumulated 100,890 shs. Creative Planning reported 13,200 shs stake. Bridgeway Cap invested in 109,400 shs. California-based Leisure Cap Mgmt has invested 0.18% in VolitionRx Limited (NYSEAMERICAN:VNRX). Lagoda Inv Mgmt Ltd Partnership has invested 3.94% in VolitionRx Limited (NYSEAMERICAN:VNRX). Morgan Stanley reported 63,400 shs.

What Price Target Has Maxim Group Given VolitionRx (OTC:VNRX)

EU: On Wednesday, 16 May, VolitionRx (OTC:VNRX) coverage was started with a Buy rating and $6 TP at Maxim Group. That’s upside potential of 166.67 % from firm’s last stock close.

The stock increased 8.70% or $0.18 during the last trading session, touching $2.25.VolitionRx Limited is downtrending after having declined 42.82% since May 17, 2017. VNRX has 145,762 volume or 3.92% up from normal. VNRX underperformed by 54.37% the S&P500.

VolitionRx Limited (NYSEAMERICAN:VNRX) is awaited to reveal earnings on August, 8., as reported by Faxor. EPS of $-0.17 is 30.77 % down from 2017’s $-0.13 EPS. Wall Street forecasts 0.00 % EPS growth as of August, 8.

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide.The firm is valued at $67.57 million. The firm develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform.Currently it has negative earnings.

VolitionRx Limited (NYSEAMERICAN:VNRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: